Pharmaceutical Executive
More than two years since the devastation inflicted by Hurricane Maria, Puerto Rico’s supply of medical products has remained largely uninterrupted, debunking common misconceptions at the time and maintaining the island’s standing as one of the most attractive life sciences manufacturing hubs.
Wednesday, Sept. 20, 2017 is a day still fresh in every Puerto Rican’s mind. On this day, Hurricane Maria arrived in Puerto Rico, becoming the first Category 5 hurricane on record to strike the US territory. Despite the magnitude of the event and the disruption it caused to the energy, water, and telecommunications infrastructure, the supply of medical products from Puerto Rico was only minimally affected without any shortage reported.
“The natural disasters we experienced in 2017 were tragic but showed the commitment and resilience of the Puerto Rican workforce. Most companies resumed with their operations only one or two weeks after the hurricanes, while some never stopped producing at all,” proudly recalls Manuel A. Laboy Rivera, secretary of the Department of Economic Development and Commerce and executive director of Puerto Rico Industrial Development Company (PRIDCO).
“There is a big misconception that there were supply issues or stockouts-this was not the case,” adds Ivan Lugo, president of INDUNIV, a nonprofit organization representing industry, govÂernment, and the academic sector in Puerto Rico. “Puerto Rico’s pharmaceutical and medical devices facilities worked closely with the FDA to ensure all plants were able to return to their regular business schedule as fast as possible.”
To read more about the pharma industry's rapid response to Maria and, now more than two years later, how Puerto Rico is maintaining its standing as one of the most attractive life sciences manufacturing hubs, view the full report
here(cycle down to page 30). The report is produced by Focus Reports and featured in Pharm Exec's December 2019 issue.
To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.